Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AKAN NASDAQ:CING NASDAQ:IMA NASDAQ:IMMP On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAKANAkanda$27.00-27.4%$7.50$2.30▼$209.02$14.31M14.491.67 million shs384,090 shsCINGCingulate$5.27+0.8%$6.44$3.20▼$11.89$64.56M-0.81461,288 shs252,926 shsIMAImageneBio$5.29-10.5%$5.71$3.94▼$18.00$56.34M0.73260,362 shs74,995 shsIMMPPrima BioMed$0.45+3.1%$0.99$0.29▼$3.53$65.73M2.2410.73 million shs463,488 shs7 Stocks That Will Be Magnificent in 2026Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAKANAkanda+19.97%-24.04%+1,065.65%+760.88%-54.64%CINGCingulate-1.88%+1.55%-11.95%-32.08%+33.42%IMAImageneBio-2.80%-1.83%+24.42%-14.47%-54.82%IMMPPrima BioMed-2.26%-6.47%+21.63%-83.50%-77.60%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAKANAkanda$27.00-27.4%$7.50$2.30▼$209.02$14.31M14.491.67 million shs384,090 shsCINGCingulate$5.27+0.8%$6.44$3.20▼$11.89$64.56M-0.81461,288 shs252,926 shsIMAImageneBio$5.29-10.5%$5.71$3.94▼$18.00$56.34M0.73260,362 shs74,995 shsIMMPPrima BioMed$0.45+3.1%$0.99$0.29▼$3.53$65.73M2.2410.73 million shs463,488 shs7 Stocks That Will Be Magnificent in 2026Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAKANAkanda+19.97%-24.04%+1,065.65%+760.88%-54.64%CINGCingulate-1.88%+1.55%-11.95%-32.08%+33.42%IMAImageneBio-2.80%-1.83%+24.42%-14.47%-54.82%IMMPPrima BioMed-2.26%-6.47%+21.63%-83.50%-77.60%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAKANAkanda 1.00SellN/AN/ACINGCingulate 2.33Hold$34.50554.65% UpsideIMAImageneBio 2.00Hold$26.50400.95% UpsideIMMPPrima BioMed 1.75Reduce$5.501,133.18% UpsideCurrent Analyst Ratings BreakdownLatest AKAN, CING, IMMP, and IMA Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/1/2026AKANAkanda Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (E+) ➝ Sell (D-)4/20/2026CINGCingulate Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)4/10/2026AKANAkanda Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)4/8/2026CINGCingulate Ascendiant Capital MarketsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$58.00 ➝ $55.003/23/2026CINGCingulate Roth MkmSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$16.00 ➝ $14.003/13/2026IMMPPrima BioMed Maxim GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeBuy ➝ Hold3/13/2026IMMPPrima BioMed Robert W. BairdSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeOutperform ➝ Neutral$7.00 ➝ $1.003/13/2026IMMPPrima BioMed Citizens JmpSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeOutperform ➝ Market Perform2/23/2026IMMPPrima BioMed Citizens JmpSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageMarket Outperform$10.002/17/2026IMMPPrima BioMed Citizens JmpSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageMarket Outperform$6.00(Data available from 5/8/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAKANAkanda$840K17.04N/AN/A$210.79 per share0.13CINGCingulateN/AN/AN/AN/A$0.31 per shareN/AIMAImageneBio$800K70.42N/AN/A$11.91 per share0.44IMMPPrima BioMed$4.08M16.11N/AN/A$0.63 per share0.71Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAKANAkanda-$4.10MN/AN/AN/AN/AN/AN/AN/AN/ACINGCingulate-$22.45M-$4.32N/AN/AN/AN/A-509.72%-172.37%5/14/2026 (Estimated)IMAImageneBio-$45.35M-$8.07N/AN/AN/AN/A-35.77%-31.78%N/AIMMPPrima BioMed-$39.78MN/AN/AN/AN/AN/AN/AN/AN/ALatest AKAN, CING, IMMP, and IMA EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/14/2026Q1 2026CINGCingulate-$0.53N/AN/AN/AN/AN/A5/7/2026Q1 2026IMAImageneBio-$0.70-$0.95-$0.25-$0.95N/AN/A3/18/2026Q4 2025CINGCingulate-$0.56-$0.84-$0.28-$0.84N/AN/A3/10/2026Q4 2025IMAImageneBioN/A$0.34N/A$0.34N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthAKANAkandaN/AN/AN/AN/AN/ACINGCingulateN/AN/AN/AN/AN/AIMAImageneBioN/AN/AN/AN/AN/AIMMPPrima BioMedN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAKANAkandaN/AN/AN/ACINGCingulate0.461.161.16IMAImageneBioN/A12.4912.49IMMPPrima BioMedN/A2.97N/ACompare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAKANAkanda1.00%CINGCingulate41.31%IMAImageneBio75.00%IMMPPrima BioMed2.32%Insider OwnershipCompanyInsider OwnershipAKANAkanda20.39%CINGCingulate4.33%IMAImageneBio5.94%IMMPPrima BioMed3.07%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAKANAkanda110530,000425,000Not OptionableCINGCingulate2012.25 million11.72 millionNot OptionableIMAImageneBio7010.65 million10.02 millionNot OptionableIMMPPrima BioMed2,021147.37 million142.85 millionOptionableAKAN, CING, IMMP, and IMA HeadlinesRecent News About These CompaniesIMMUTEP ALERT: Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against Immutep Ltd.19 minutes ago | globenewswire.comIMMP Shareholder Alert: Immutep Limited Securities Class Action Lawsuit - Investors Should Contact The Gross Law FirmMay 8 at 9:00 AM | globenewswire.comIMMP Investors Have Opportunity to Lead Immutep Limited Securities Fraud Lawsuit with the Schall Law FirmMay 7 at 5:28 PM | globenewswire.comROSEN, GLOBAL INVESTOR COUNSEL, Encourages Immutep Ltd. Investors to Secure Counsel Before Important Deadline in Securities Class Action - IMMPMay 7 at 4:04 PM | newsfilecorp.comNROSEN, A LEADING LAW FIRM, Encourages Immutep Ltd. Investors to Secure Counsel Before Important Deadline in Securities Class Action - IMMPMay 7 at 4:04 PM | globenewswire.comBronstein, Gewirtz & Grossman LLC Urges Immutep Limited Investors to Act: Class Action Filed Alleging Investor HarmMay 7 at 12:00 PM | newsfilecorp.comNIMMP CLASS ACTION NOTICE: Faruqi & Faruqi, LLP Reminds Immutep (IMMP) Investors of Securities Class Action Deadline on July 6, 2026May 7 at 11:22 AM | newsfilecorp.comNINVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Immutep Limited of Class Action Lawsuit and Upcoming Deadlines - IMMPMay 7 at 10:00 AM | prnewswire.comPortnoy Law Firm Announces Class Action on Behalf of Immutep Limited InvestorsMay 7 at 9:39 AM | globenewswire.comIMMUTEP LIMITED (IMMP) INVESTOR ALERT Investors With Large Losses in Immutep Limited Should Contact Bernstein Liebhard LLP To Discuss Their RightsMay 7 at 9:03 AM | globenewswire.comPrima BioMed (NASDAQ:IMMP) Share Price Passes Below Fifty Day Moving Average - Should You Sell?May 7 at 6:23 AM | marketbeat.comIMMP Stockholder Alert: Shareholder Rights Law Firm Robbins LLP Reminds Investors of the Class Action Lawsuit Against Immutep LimitedMay 6 at 4:26 PM | prnewswire.comIMMP DEADLINE ALERT: Faruqi & Faruqi, LLP Reminds Immutep (IMMP) Investors of Securities Class Action Deadline on July 6, 2026May 6 at 2:08 PM | globenewswire.comROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Immutep Ltd. Investors to Secure Counsel Before Important Deadline in Securities Class Action - IMMPMay 6 at 12:30 PM | newsfilecorp.comNGainey McKenna & Egleston Announces A Class Action Lawsuit Has Been Filed Against Immutep Limited American Depository Receipts (IMMP)May 6 at 12:25 PM | globenewswire.comRosen Law Firm Urges Immutep Ltd. (NASDAQ: IMMP) Stockholders to Contact the Firm for Information About Their RightsMay 6 at 12:24 PM | businesswire.comBronstein, Gewirtz & Grossman LLC Urges Immutep Limited Investors to Act: Class Action Filed Alleging Investor HarmMay 6 at 12:00 PM | globenewswire.comInvestor Notice: Robbins LLP Informs Investors of the Immutep Limited Class ActionMay 5 at 6:07 PM | businesswire.comSHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors It Has Filed a Complaint to Recover Losses Suffered by Purchasers of Immutep Limited American Depositary Receipts and Sets a Lead Plaintiff Deadline of July 6, 2026May 5 at 3:41 PM | globenewswire.comRosen Law Firm Encourages Immutep Ltd. Investors to Inquire About Securities Class Action Investigation - IMMPMay 5 at 2:54 PM | prnewswire.comIMMP Investor News: If You Have Suffered Losses in Immutep Ltd. (NASDAQ: IMMP), You Are Encouraged to Contact The Rosen Law Firm About Your RightsMay 4, 2026 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesMicrosoft’s Copilot Problem Isn’t What You ThinkBy Chris Markoch | April 12, 2026The $600 Billion Buy Signal For SanDisk Stock By Jeffrey Neal Johnson | April 15, 2026GPU Prices Are Surging—3 Ways to Play the AI Chip ShortageBy Thomas Hughes | April 14, 2026PepsiCo Stock Reversal Points Toward New All-Time HighsBy Thomas Hughes | April 16, 2026RPM International's Blowout Quarter Sparks a 15% Rally By Thomas Hughes | April 10, 2026AKAN, CING, IMMP, and IMA Company DescriptionsAkanda NASDAQ:AKAN$27.00 -10.19 (-27.40%) Closing price 04:00 PM EasternExtended Trading$27.57 +0.57 (+2.11%) As of 04:20 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Akanda Corp., through its subsidiaries, engages in the cultivation, manufacture, and distribution of cannabis products to patients worldwide. It offers medicinal-grade cannabis and cannabis based medical and wellness products. The company was incorporated in 2021 and is headquartered in New Romney, the United Kingdom.Cingulate NASDAQ:CING$5.27 +0.04 (+0.76%) Closing price 04:00 PM EasternExtended Trading$5.26 0.00 (-0.09%) As of 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Cingulate Inc., a biopharmaceutical company, focuses on the development of pharmaceutical products for the treatment of attention deficit/hyperactivity disorder and anxiety in the United States. The company's stimulant medications are CTx-1301 (dexmethylphenidate), which is in phase 3 clinical trial, as well as CTx-1302 (dextroamphetamine), which is in investigational new drug application development for the treatment of attention deficit/hyperactivity disorder intended for children, adolescents, and adults. It also focuses on developing CTx-2103 that is in a formulation stage for the treatment of anxiety. The company was founded in 2012 and is headquartered in Kansas City, Kansas.ImageneBio NASDAQ:IMA$5.29 -0.62 (-10.49%) Closing price 04:00 PM EasternExtended Trading$5.61 +0.32 (+6.05%) As of 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.ImageneBio, Inc., a clinical-stage biotechnology company, develops therapeutics for immunological and inflammatory diseases. Its lead product includes IMG-007, a non-depleting anti-OX40 mAb that has completed Phase 2a clinical trials for the treatment of atopic dermatitis and alopecia areata. The company was formerly known as Ikena Oncology, Inc. and changed its name to ImageneBio, Inc. in July 2025. ImageneBio, Inc. is headquartered in San Diego, California.Prima BioMed NASDAQ:IMMP$0.45 +0.01 (+3.15%) Closing price 04:00 PM EasternExtended Trading$0.45 0.00 (0.00%) As of 04:11 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Immutep Limited, a clinical-stage biotechnology company, engages in developing novel LAG-3 Immunotherapy for cancer and autoimmune diseases. The company is involved in advancing therapeutics related to Lymphocyte Activation Gene-3 (LAG-3), a cell surface molecule that plays a vital role in regulating the immune system. Its LAG-3 immunotherapies are designed to harness and strengthen the power of patients' immune systems to fight cancer and autoimmune disease. Its lead product candidate is eftilagimod alpha (efti or IMP321) for the treatment of different types of cancers. The trials that efi is being evaluated in include TACTI-002, a Phase II clinical trial for the treatment of head and neck squamous cell carcinoma (HNSCC) and non-small cell lung cancer (NSCLC); TACTI-003, a Phase IIb clinical trial to treat HNSCC; and INSIGHT-003, a Phase I clinical trial for the treatment of NSCLC, as well as INSIGHT-005, a Phase I/IIa clinical trial to treat solid tumors. In addition, it offers IMP761, an agonist of lymphocyte activation gene 3 for autoimmune disease; IMP701, an antagonist antibody that acts to stimulate T cell proliferation in cancer patients; and IMP731, a depleting antibody that removes T cells involved in autoimmunity. The company has collaboration agreements with GlaxoSmithKline, Novartis, CYTLIMIC Inc., Merck & Co., Inc., Institute of Clinical Cancer Research, Merck KGaA, and EOC Pharma. The company was formerly known as Prima BioMed Ltd and changed its name to Immutep Limited in November 2017. The company was incorporated in 1987 and is headquartered in Sydney, Australia. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas SoundHound’s Bottom Is In—Inflection and 50% Upside Ahead? Rocket Lab Posts Record Q1 Revenue, Raises Q2 Guidance Hims & Hers Earnings Preview: The Novo Nordisk Shift Puts GLP-1 Strategy in Focus AppLovin Pops After Earnings With Growth Catalysts in Sight Dutch Bros Q1 Earnings: The Newest Starbucks Rival Faces Its First Big Reality Check The AI Fear Around Datadog Stock May Have Been Completely Wrong Amprius Technologies Ups the Voltage on Forward Outlook Why Lam Research Still Looks Like a Buy After a 300% Rally Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
